Stage
No active trials
Next date
None yet
Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Infertility
- Main trialPhase 3
- “The primary objective of this study is to confirm the efficacy of a single oral 900 mg dose of nolasiban versus placebo to increase the ongoing clinical pregnancy rate at 10 weeks post-embryo transfer (ET) day.”In the company’s words, NCT03758885 on ClinicalTrials.gov
Other drugs for Infertility
- FertiloGameto, Inc. · Phase 3
- Follitropin alfa/lutropin alfaMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Phase 3
- PKB171Prokrea BCN, S.L. · Phase 2/3
- HMGGranata Bio Corporation · Phase 3
- MibavademabRegeneron · Phase 2
- Teverelix DPAntev Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 21 Nov 2019 | Study of Nolasiban to Increase Pregnancy Rates in Women Undergoing IVF | |
| Phase 2Authorised | not given | A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multicenter Trial Evaluating the Effects of Two Dosing Regimens of Nolasiban on Uterine Contractility and Endocrine Parameters |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026